NCT06295926View on ClinicalTrials.gov

Serplulimab Combined With CCRT for LS-SCLC.

PHASE2RecruitingINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

April 4, 2024

Primary Completion Date

January 25, 2027

Study Completion Date

December 31, 2027

Conditions
Small Cell Lung Cancer
Interventions
DRUG

Serplulimab

Undergo 4 cycles of synchronous radiotherapy and chemotherapy combined with Sintilimab immunotherapy, followed by Sintilimab monotherapy for maintenance treatment until disease progression or up to 1 year.

Trial Locations (1)

100730

RECRUITING

Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER